Asian crisis hits Acuson revenues

Article

The ongoing financial crisis in Asia and the strong U.S. dollar conspired to put the brakes on Acuson's second-quarter financial results. The Mountain View, CA, company last month reported slightly higher revenues for the period (end-July), while net

The ongoing financial crisis in Asia and the strong U.S. dollar conspired to put the brakes on Acuson's second-quarter financial results. The Mountain View, CA, company last month reported slightly higher revenues for the period (end-July), while net income declined.

For the quarter, Acuson turned in revenues of $113.3 million, up only marginally compared with sales of $112.7 million in the second quarter of 1997. The company's net income fell to $4.1 million, compared with a profit of $5.7 million in the same period last year.

Acuson's international revenues fell 16% during the period, due to the Asian crisis and the strong dollar, according to chairman and CEO Samuel Maslak. The company's outlook for the rest of the year is positive, however. The U.S. ultrasound market continues to show strength, and Europe is recovering, Maslak said.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.